echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Under the trend of innovation, the upstream and downstream of the pharmaceutical industry chain are increasing investment in research and development

    Under the trend of innovation, the upstream and downstream of the pharmaceutical industry chain are increasing investment in research and development

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At present, the three quarterly reports of listed companies in 2022 have been disclosed one after another, and at the same time, the R&D expenses of various pharmaceutical companies have also been released
    .
    From the perspective of pharmaceutical companies that have disclosed R&D expenditure data, in the first three quarters, many pharmaceutical companies have increased their R&D expenditure investment significantly, and the innovation results have been fruitful
    .

     
    The upstream and downstream of the pharmaceutical industry chain are increasing investment in research and development (Image source: Pharma.
    com)
     
    Pharmaceutical companies are investing in R&D increasing
     
    Taking Warner Pharma as an example, on October 31, Warner Pharma disclosed its third quarter report
    for 2022.
    According to the report, the company's operating income in the first three quarters reached 927 million yuan, a year-on-year increase of 14.
    97%; In the first three quarters, the net profit attributable to shareholders of listed companies was about 124 million yuan, a year-on-year increase of 20.
    22%.

    While its net profit increased steadily by 20%, its R&D investment rose sharply; The total R&D investment in the first three quarters was about 58.
    7 million yuan, a year-on-year increase of 29.
    49%.


     
    With continuous investment, up to now, Warner Pharmaceutical has obtained 41 registration approvals for chemical pharmaceutical preparations, 19 registration approvals for traditional Chinese medicine preparations and 36 products with registration number A for chemical APIs
    .
    It has 1 exclusive preparation variety, 5 exclusive dosage form varieties, 6 consistency evaluation products, 32 product categories have been listed in the national medical insurance list, and 13 product categories have been listed in the national essential drugs list
    .

     
    In the first three quarters of Ling Pharmaceutical, the company's R&D expenses reached 552 million yuan, and the R&D expense rate increased by 2.
    6%
    year-on-year.
    Through continuous high R&D investment, Yiling Pharmaceutical has accelerated the transformation of traditional Chinese medicine achievements, and the company has developed 13 innovative patented traditional Chinese medicines, covering the treatment of
    cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and other diseases.
    In addition, Sinovac Pharmaceutical released the third quarterly report of 2022, showing that R&D investment continued to increase, also increasing by 63.
    46% year-on-year.
    .
    .

     
    It is worth noting that in order to accelerate innovation and research and development, since the beginning of this year, a large number of pharmaceutical companies have also opened a fundraising model
    .
    According to Wind data, as of July 27, 32 pharmaceutical listed companies have launched additional issuance plans during the year, with a total of 34.
    082 billion yuan to be raised; 15 companies have completed the fixed increase plan, and the actual total amount of funds raised is nearly 32 billion yuan
    .

     
    On the whole, it is obvious that pharmaceutical companies attach importance to R&D and innovation, and the firmness
    of domestic pharmaceutical companies to take the road of innovation and sustainable development.
    In fact, in addition to pharmaceutical companies, many companies in the upstream and downstream of the pharmaceutical industry chain have embarked on the road of transformation and innovation, and R&D investment is also continuing to rise
    .

     
    The driving force for the development of innovative pharmaceutical machine enterprises
     
    At present, the pharmaceutical equipment industry has already embarked on the road of innovation, and R&D investment is also increasing
    .
    Among them, Dongfulong 2 invested 285 million yuan in R&D in 021, a year-on-year increase of 82.
    2%, accounting for 6.
    79%
    of operating income.
    The number of R&D personnel has also increased from 396 (14.
    88%) in 20 years to 677 (18.
    44%)
    in 21 years.

     
    It is understood that the company through self-research and cooperative research and development and other forms to enhance its own research and development strength, has successfully developed a variety of core equipment, patent achievements are rich, as of the end of 21, the company has 1154 effective patented technologies, 149 software copyrights, including 21 new authorized patents 139.


     
    Chutian Technology has also been focusing on innovation capabilities, and invested 307 million yuan in research and development in the first three quarters of 2021, a year-on-year increase of 60.
    7%.

    With the continuous increase in innovation investment, Chutian Technology is ushering in fruitful results
    .
    Compared with last year, the company has added five new product lines and dozens of new products
    .

     
    In addition, Canaan Technology said when releasing its first quarter 2022 performance forecast that the company will continue to increase its efforts to develop new markets and invest in research and development of
    new products.

     
    epilogue
     
    Industry analysis believes that from the perspective of the actions of pharmaceutical machine head enterprises in R & D and innovation, innovation has become the general trend
    of development of the pharmaceutical machinery industry.
    In the future, in order to maintain competitiveness, better meet the demand of the pharmaceutical market, and achieve import substitution, more and more domestic pharmaceutical machinery enterprises with R&D strength and capital will increase investment in innovation and R&D, diversify and differentiate equipment and technology to improve product quality, technology, and expand production capacity
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.